Etzer Darout, an analyst from BMO Capital, maintained the Buy rating on AstraZeneca (AZN – Research Report). The associated price target remains the same with $88.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Etzer Darout’s rating is based on AstraZeneca’s strong financial performance and strategic outlook. The company reported a slight increase in total revenue and aligned core operating income with consensus expectations. AstraZeneca anticipates revenue growth in the high-single-digit range and expects EPS growth in the low-double-digit range, indicating a positive financial trajectory.
Moreover, AstraZeneca is committed to increasing its investment in manufacturing and technology, which is expected to drive future growth. Despite potential challenges such as the China investigation and various market dynamics, AstraZeneca’s growth momentum is expected to continue. The company also benefits from a strong pipeline and expansion into higher-margin products, suggesting that its current share price does not fully reflect its potential value.
AZN’s price has also changed slightly for the past six months – from $79.250 to $72.360, which is a -8.69% drop .